Non-peptide GnRH agents
Patent 6218426 Issued on April 17, 2001. Estimated Expiration Date: 
March 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesGnRH Antagonists VI GNRH antagonists XIII Patent #: 5506207 InventorsAssigneeApplicationNo. 259206 filed on 03/01/1999US Classes:514/448, C=O bonded directly to the hetero ring (X is chalcogen)514/471, Nitrogen containing514/613, Carboxamides (i.e., R-C(=O)-N, wherein R is a radical having carbon bonded directly to the C(=O)-N or is hydrogen and wherein any substituent attached to nitrogen will be referred to as E)514/634, Guanidines (i.e., N=C(-N)-N)549/72, Nitrogen or chalcogen attached indirectly to the hetero ring by nonionic bonding549/461, Having -C(=X)-, wherein X is chalcogen, attached directly or indirectly to the tricyclo ring system by nonionic bonding549/483, Having -C(=X)-, wherein X is chalcogen, bonded directly to the hetero ring549/487, Nitrogen bonded directly to the -C(=X)- group560/190, Polycarboxylic acid564/161, Substituent Q contains benzene ring564/170, Hydroxy, bonded directly to carbon, or ether in substituent Q (H of -OH may be replaced by a substituted or unsubstituted ammonium ion or a Group IA or IIA light metal)564/237Benzene ring containingExaminersPrimary: Killos, Paul J.Foreign Patent References
International ClassesA01N 043/06C07C 069/34 AbstractNon-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and are defined variables: ##STR1##Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.Other References
Field of SearchThe additional hetero ring is one of the cyclos in a polycyclo ring systemRing nitrogen in the polycyclo ring system C=O bonded directly to the hetero ring (X is chalcogen) Nitrogen containing Acyclic Guanidines (i.e., N=C(-N)-N) The acyclic carbon or acyclic carbon chain is further unsubstituted or alkyl substituted only (e.g., tryptophane, etc.) Acyclic nitrogen bonded directly to the acyclic carbon or acyclic carbon chain Nitrogen or chalcogen attached indirectly to the hetero ring by nonionic bonding Having -C(=X)-, wherein X is chalcogen, attached directly or indirectly to the tricyclo ring system by nonionic bonding Having -C(=X)-, wherein X is chalcogen, bonded directly to the hetero ring Nitrogen bonded directly to the -C(=X)- group Substituent Q contains benzene ring Hydroxy, bonded directly to carbon, or ether in substituent Q (H of -OH may be replaced by a substituted or unsubstituted ammonium ion or a Group IA or IIA light metal) Benzene ring containing Polycarboxylic acid |
| ||||||||||||||
